Even if this mechanism may not be unique [192], the administration of both products of the NXNL1 gene provides the rational for a therapy aimed at preventing or delaying the loss of central vision in all genetic forms of RP. The gene discussed is NXNL1; the disease is retinitis pigmentosa 1.